Literature DB >> 22127224

Polypoidal choroidal vasculopathy: simultaneous indocyanine green angiography and eye-tracked spectral domain optical coherence tomography findings.

Samira Khan1, Michael Engelbert, Yutaka Imamura, K Bailey Freund.   

Abstract

PURPOSE: To describe simultaneous scanning laser ophthalmoscope indocyanine green angiographic and eye-tracked spectral-domain optical coherence tomography findings in eyes with polypoidal choroidal vasculopathy (PCV).
METHODS: Eighteen eyes of 18 patients with PCV because of a variety of different diagnoses were imaged with simultaneous scanning laser ophthalmoscope indocyanine green angiography and eye-tracked spectral-domain optical coherence tomography to localize the polyps and their associated vascular structures with respect to the retinal layers.
RESULTS: Regardless of the underlying diagnosis, simultaneous scanning laser ophthalmoscope indocyanine green angiography and eye-tracked spectral-domain optical coherence tomography imaging localized the polypoidal structures of PCV to within larger Type 1 neovascular complexes occurring within or above Bruch membrane. In 8 eyes, PCV appeared to adhere to the undersurface of an elevated retinal pigment epithelial detachment. In 1 eye, a PCV lesion was detected within the neurosensory retina having apparently eroded through the overlying retinal pigment epithelium.
CONCLUSION: Simultaneous scanning laser ophthalmoscope indocyanine green angiography and eye-tracked spectral-domain optical coherence tomography demonstrate that a majority of PCV represents a variant of the Type 1 neovascular growth pattern, which can occur in a variety of different neovascularized maculopathies. Polypoidal choroidal vasculopathy lesions appear to originate from long-standing choroidal neovascularization, rather than from the choroidal vasculature itself. Given these observations, PCV would be more accurately described as a neovasculopathy rather than as a choroidal vasculopathy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22127224     DOI: 10.1097/IAE.0b013e31823beb14

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  37 in total

1.  Baseline polyp size as a potential predictive factor for recurrence of polypoidal choroidal vasculopathy.

Authors:  Hae Min Kang; Hyoung Jun Koh; Sung Chul Lee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-12-21       Impact factor: 3.117

2.  Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection.

Authors:  Masaaki Saito; Mariko Kano; Kanako Itagaki; Shigeyuki Ise; Kimihiro Imaizumi; Tetsuju Sekiryu
Journal:  Jpn J Ophthalmol       Date:  2015-09-09       Impact factor: 2.447

3.  Angiographic features of transgenic mice with increased expression of human serine protease HTRA1 in retinal pigment epithelium.

Authors:  Sandeep Kumar; Zachary Berriochoa; Balamurali K Ambati; Yingbin Fu
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-05-22       Impact factor: 4.799

4.  Retinal pigment epithelial tears in the era of intravitreal pharmacotherapy: risk factors, pathogenesis, prognosis and treatment (an American Ophthalmological Society thesis).

Authors:  David Sarraf; Anthony Joseph; Ehsan Rahimy
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

5.  Pigment epithelial tears after ranibizumab injection in polypoidal choroidal vasculopathy and typical age-related macular degeneration.

Authors:  Joo Youn Shin; Moonjung Choi; Byunghoon Chung; Suk Ho Byeon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-03-07       Impact factor: 3.117

6.  Dual-stage deep learning framework for pigment epithelium detachment segmentation in polypoidal choroidal vasculopathy.

Authors:  Yupeng Xu; Ke Yan; Jinman Kim; Xiuying Wang; Changyang Li; Li Su; Suqin Yu; Xun Xu; Dagan David Feng
Journal:  Biomed Opt Express       Date:  2017-08-10       Impact factor: 3.732

7.  Earlier therapeutic effects associated with high dose (2.0 mg) Ranibizumab for treatment of vascularized pigment epithelial detachments in age-related macular degeneration.

Authors:  C K Chan; P Abraham; D Sarraf; A S D Nuthi; S G Lin; C A McCannel
Journal:  Eye (Lond)       Date:  2014-10-03       Impact factor: 3.775

8.  Polypoidal choroidal vasculopathy in patients aged less than 50 years: characteristics and 6-month treatment outcome.

Authors:  Young Suk Chang; Jae Hui Kim; Jong Woo Kim; Tae Gon Lee; Chul Gu Kim; Sung Won Cho
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-09-19       Impact factor: 3.117

9.  Prospective evaluation of subretinal vessel location in polypoidal choroidal vasculopathy (PCV) and response of hemorrhagic and exudative PCV to high-dose antiangiogenic therapy (an American Ophthalmological Society thesis).

Authors:  Gregg T Kokame
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

10.  Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial.

Authors:  Adrian Koh; Timothy Y Y Lai; Kanji Takahashi; Tien Y Wong; Lee-Jen Chen; Paisan Ruamviboonsuk; Colin S Tan; Chrystel Feller; Philippe Margaron; Tock H Lim; Won Ki Lee
Journal:  JAMA Ophthalmol       Date:  2017-11-01       Impact factor: 7.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.